Table 2.
Cost-effectiveness analysis.
| Strategies | Life years | QALYs | Total costs (US$) | ICER (US$/QALY) (NI versus C) |
|---|---|---|---|---|
| In randomized patients | ||||
| NI | 2.33 | 1.45 | 295,988 | 475,677 |
| C | 1.87 | 1.19 | 168,111 | |
| Incremental (NI versus C) | 0.46 | 0.27 | 127,877 | |
| In patients with epithelioid histology | ||||
| NI | 2.38 | 1.48 | 313,857 | 760,955 |
| C | 2.15 | 1.34 | 205,508 | |
| Incremental (NI versus C) | 0.23 | 0.14 | 108,349 | |
| In patients with non-epithelioid histology | ||||
| NI | 1.97 | 1.25 | 268,724 | 418,348 |
| C | 1.17 | 0.79 | 72,783 | |
| Incremental (NI versus C) | 0.81 | 0.47 | 195,941 | |
C, pemetrexed plus cisplatin/carboplatin; ICER, incremental cost-effectiveness ratio; NI, nivolumab plus ipilimumab; QALYs, quality-adjusted life years.